Scinai Immunotherapeutics Ltd. - news published 139 - readings 1.432

BACK
Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd.

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions (Form 6-K)

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions Scinai files an application for Euro 12 million grant to fund next stage of development ● Pincell's monoclonal antibody, PC111, is in development for treating Pemphigus, Steven Johnson's Syndrome (SJS) and Toxic Epidermal Necrolysis (T ...

Continue reading
27.03.2025
Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd.

Amendment to Registration Statement by Foreign Issuer (Form F-1/A)

As filed with the United States Securities and Exchange Commission on March 11, 2025. Registration No. 333-285547 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Scinai Immunotherapeutics Ltd. (Exact name of registrant as specified in its charter) Israel 2836 Not Applicable ...

Continue reading
11.03.2025
Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd.

Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board

JERUSALEM, Nov. 27, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, announced today that Dr. Jonathan Sadeh has been appointed as ...

Continue reading
27.11.2024
Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd.

Scinai Publishes Financial Results and Provides Business Update; Shareholders’ Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million Form 6 K

Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million JERUSALEM, November 22, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology ...

Continue reading
25.11.2024
Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd.

Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

Business Update & Recent Highlights Conversion of EIB Loan into Equity bringing shareholders' equity to $10 million On August 21, 2024, the Company announced that it had closed a Loan Restructuring Agreement, which included an amendment and restatement to the amended Finance Contract with the European Investment Bank (the "EIB"). In connection with the transactio ...

Continue reading
22.11.2024
Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd.

Scinai Leadership to Showcase Company’s cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024

About Scinai Immunotherapeutics Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet ...

Continue reading
31.10.2024
Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd.

Jerusalem BioPark, 2nd FloorHadassah Ein Kerem CampusJerusalem, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERSTo Be Held on November 21, 2024 Form 6 K

Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on November 21, 2024 The Annual General Meeting of Shareholders of Scinai Immunotherapeutics Ltd. (the "Company") will be held at the offices of Goldfarb Gross Seligman & Co., One Azrieli Center, Tel Aviv, Israel on November 21, 202 ...

Continue reading
15.10.2024
Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd.

Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti IL 17A/F VHH Antibodies

The virtual panel discussion will feature: · Mr. Amir Reichman , CEO of Scinai, who will serve as moderator; · Dr. Tamar Ben Yedidia , Chief Scientific Officer at Scinai; · Prof. Michael Schoen , Director of Dermatology and Venerology at the University Medical Center Göttingen, Germany (UMG) and an independent medical consultant of Scinai; and · Prof. Matthias Dobbelstein ...

Continue reading
16.09.2024